GenSight Biologics S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSGTF research report →
Companywww.gensight-biologics.com
GenSight Biologics S. A. , a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
- CEO
- Laurence Rodriguez
- IPO
- 2018
- Employees
- 16
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $30.99M
- P/E
- -1.38
- P/S
- 14278.80
- P/B
- -0.66
- EV/EBITDA
- -2.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1168400.00%
- Net Margin
- -1203600.00%
- ROE
- 42.20%
- ROIC
- 1515.43%
Growth & Income
- Revenue
- $999.63 · -99.93%
- Net Income
- $-12,031,491 · 14.07%
- EPS
- $-0.08 · 52.24%
- Op Income
- $-11,700,615
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $0.48
- 52W Low
- $0.19
- 50D MA
- $0.19
- 200D MA
- $0.19
- Beta
- 0.61
- Avg Volume
- 402.592
Get TickerSpark's AI analysis on GSGTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GSGTF Coverage
We haven't published any research on GSGTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GSGTF Report →